Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025

23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio

SANTA CLARA, Calif. – May 15, 2025 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced today that data from 23 company-sponsored and funded studies, including three late-breaking presentations, will be presented at EuroPCR 2025 to be held May 20-23rd in Paris. These studies will feature data from Shockwave’s pioneering cardiovascular portfolio, including its market-leading Shockwave Intravascular Lithotripsy (IVL) platform and innovative Reducer technology that are transforming the treatment of cardiovascular disease.1

„The breadth of research data being presented on our products at EuroPCR 2025 reflects our relentless drive to address the unmet needs of patients suffering from cardiovascular disease,“ said Nick West, M.D., Chief Medical Officer, Shockwave Medical. „As a pioneer in IVL and coronary sinus reduction technologies, we are committed to harnessing these clinical insights to drive innovations that will shape new standards of treatment and help physicians improve treatment for their patients worldwide.“

Key data highlights are outlined below. A full list of presentations can be found online.

  • Late-Breaking Presentations:
    • EMPOWER CAD Study: Women with Calcified Coronary Arteries Treated with IVL
      • Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Margaret McEntegart, M.D., Columbia University Medical Center.
      • EMPOWER CAD is a prospective, multi-center, all-female study investigating the use of coronary intravascular lithotripsy (IVL) for treating calcified lesions in women with coronary artery disease. It aims to confirm the benefits of IVL in a post-market, real-world, all-comers population of female patients.
    • Randomized Comparison of Lithotripsy vs. Conventional Preparation of Calcified Lesions (BALI)
      • Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Andreas Torp Kristensen, M.D., Arhus University Hospital.
      • BALI is a multicenter, randomized trial that will show whether routine addition of balloon lithotripsy improves outcomes compared with conventional preparation alone.
    • Rotational Atherectomy, Lithotripsy or Laser for Calcified Coronary Stenosis. One-Year Outcomes (RollerCoastr-EPIC22)2
      • Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Alfonso Jurado, M.D., Ph.D., La Paz University Hospital.
      • RollerCoastr-EPIC22 is a randomized controlled trial that is investigating the effectiveness of rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), and intravascular lithotripsy (IVL) in treating calcified coronary stenosis, with a focus on one-year outcomes.
  • Poster Presentation: Coronary Sinus Reducer for Patients with Refractory Angina and Non-Obstructive Coronary Disease – ANOCA. May 22, 11:29 a.m. CEST, presented by Ranil de Silva, M.D., Imperial College London.

In addition to the data being presented at EuroPCR, Shockwave Medical will support educational programs, in-booth presentations and training opportunities for attendees throughout the meeting, including two sponsored session symposia:

  • Treat Calcium Right the First Time: New Considerations for PCI Planning and Device Selection to Optimize Outcomes
    • Room 242AB. May 21, 12:30 – 2:00 p.m. CEST
    • Attendees will explore the role of IVL as a first-line treatment strategy for managing coronary artery calcification (CAC) by observing a recorded case and listening to a panel discussion.
    • Moderator: Emanuele Barbato, M.D., Sant’Andrea University Hospital
    • Panelists:
      • Angela McInerney, M.D., University Hospital Galway
      • Margaret McEntegart, M.D., Columbia University Medical Center
      • Niels Tuhe Olsen, Rigshospitalet
      • Marco Pavani, M.D., AOU San Luigi Gonzaga
      • Simon Wilson, M.D., St George’s University NHS Trust
  • Road to Relief – Effective Treatment for Patients with Refractory Angina with Shockwave Reducer
    • Room 251. May 22, 12:30 – 1:30 p.m. CEST
    • Attendees will hear from panelists to understand the true impact and occurrence of refractory angina, a major public health problem that has a treatment option.
    • Moderator: James Spratt, M.D., St. George’s University NHS Trust
    • Panelists:
      • Ranil de Silva, M.D., Royal Brompton Hospital
      • Mariusz Tomaniak, M.D., Ph.D., FESC, Medical University of Warsaw
      • Felix Woitek, M.D., University Hospital Carl Gustav Carus Dresden Heart Center
      • Tommaso Gori, M.D., Ph.D., University Medical Center Johannes Gutenberg University Mainz

Finally, Shockwave Medical’s IVL and Reducer technology will be prominently showcased across 13 scientific sessions of interest:

Tuesday, May 20

  • Coronary Sinus Reducer Implantation: When All is Not Lost – The Exchange. May 20, 1:15 – 2:15 p.m. CEST, presented by Kevin Cheng

Wednesday, May 21

  • Optimizing our Approach to Calcium Treatment – The Exchange. 8:30 – 9:30 a.m. CEST, presented by Breda Hennessey and Yongcheol Kim
  • Calcified Nodules: A Different Beast? – Theatre Bleu. 8:30 – 9:30 a.m. CEST, presented by Emanuele Barbato
  • A National Audit of Coronary Sinus Reducer Implantation in the United Kingdom – Abstracts Room 342B. 9:45 – 10:45 a.m. CEST, presented by Kevin Cheng
  • Safety and Efficacy of Intravascular Lithotripsy for Calcified Left Main Disease: A Subgroup Analysis of Shock India Registry – Abstract & Case Corner. 9:45 – 10:45 a.m. CEST, presented by Ankush Gupta
  • Coronary Lithotripsy in Calcified Lesions: Preliminary Results from the GISE Shockcalcium Registry – Room 241. 11:15 a.m. – 12:15 p.m. CEST, presented by Guilia Nardi
  • Treatment of Refractory Angina Pectoris Associated with Coronary Microcirculation Dysfunction – Abstract & Case Corner B. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak

Thursday, May 22

  • Calcium Modification: Contemporary Comparisons of Atherectomy and IVL – Room 241. 8:30 – 9:30 a.m. CEST, presented by Pedro Lemos and Sheeran Al Shaikh
  • Coronary Sinus Reducer for Patients with Refractory Angina & Non-Obstructive Coronary Disease (REDUCER I – ANOCA) – The Exchange. 11:15 a.m. – 12:15 p.m. CEST, presented by Ranil de Silva
  • FRANCE-LILI Registry: Advancing Intravascular Lithotripsy in In-Stent Restenosis Treatment – Room 341, 1:45 – 2:45 p.m. CEST, presented by Guillaume Cayla
  • Efficacy of CS Reducer in Refractory Angina Pectoris Associated with Microvascular Dysfunction – Room Arlequin. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak
  • Effectiveness of Coronary Sinus Reducer Implantation in a Routine Clinical Practice: 12-month Outcomes – Room Arlequin. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak
  • Intravascular Coronary Lithotripsy Prior to DCB Angioplasty – Room 252A. 4:15 – 5:15 p.m. CEST, presented by Franz Kleber

Shockwave Medical will be offering three days of valuable training village sessions with an immersive IVL virtual reality experience as well as best practice presentations and hands-on simulator lessons with both Shockwave IVL and Shockwave Reducer technology. For more information on Shockwave Medical’s presence at EuroPCR and to register for hands-on sessions, please visit our EuroPCR 2025 microsite. Visit us at EuroPCR in booth F19 and learn more about our portfolio online.

About Shockwave Medical
Shockwave Medical Inc., part of Johnson & Johnson MedTech, is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Its Reducer technology, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom, is designed to provide relief to the millions of patients worldwide suffering from refractory angina by redistributing blood flow within the heart. Learn more at www.shockwavemedical.com.

Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation, we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Shockwave Medical, Inc. is part of Johnson & Johnson MedTech.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Shockwave Medical, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Shockwave Medical, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.as a result of new information or future events or developments.

Media Contact
Lindsey Diaz-MacInnis
ldiazmac@it.jnj.com

Charlene DeBar
cdebar1@its.jnj.com

1: Shockwave Medical’s Reducer technology is under clinical evaluation in the U.S. and CE Marked in the European Union and United Kingdom.
2: RollerCoastr-EPIC-22 is not a Shockwave Medical-sponsored study.